Promega Opposes High Court Review Of Invalidity Ruling In Amplification Patents

(September 11, 2015, 11:16 AM EDT) -- WASHINGTON, D.C. — Promega Corp. asserts in an opposition brief filed Aug 26 that the U.S. Supreme Court should not review a lower court’s interpretation and application of an infringement statute in a ruling that reversed an order vacating Promega’s $52 million victory in a patent and licensing dispute over gene-testing technology (Life Technologies Corp., et al. v. Promega Corp., No. 14-1538, U.S. Sup.).

(Opposition brief available. Document #78-150921-003B.)

Promega asserted U.S. patent Nos. 5,843,660, 6,221,598, 6,479,235 and 7,008,771 (the Promega patents, collectively), as well as...
To view the full article, register now.